GO:0046329 negative regulation of JNK cascade: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046329 (negative regulation of JNK cascade) describes any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the JNK cascade.
• The JNK cascade is a stress-activated MAP kinase pathway, and its negative regulation is essential for preventing excessive inflammatory, apoptotic, and proliferative signaling.
• Key negative regulators include phosphatases (e.g., DUSPs), scaffold proteins (e.g., paxillin), and secreted antagonists such as Sfrp4 that repress Ror2/Jnk signaling in osteoclasts.
• Dysregulation of JNK cascade inhibition is implicated in cancer, neurodegeneration, metabolic liver disease, and bone resorption disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of negative regulators within this GO term.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study negative regulation of JNK cascade in disease-relevant contexts.
Description
The JNK cascade is a mitogen-activated protein kinase (MAPK) signaling module that is strongly activated by cellular stress, inflammatory cytokines, and developmental cues. Because unrestrained JNK activity can drive apoptosis, inflammation, and tissue remodeling, cells deploy multiple layers of negative regulation to keep this pathway in check. GO:0046329, negative regulation of JNK cascade, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of signal transduction mediated by the JNK cascade. Understanding this GO term is critical for researchers studying stress signaling, immune homeostasis, and tissue-specific disease mechanisms. Mechanistically, negative regulation of the JNK cascade can occur at the level of upstream receptors, scaffold complexes, kinase activation, or downstream substrate phosphorylation. For example, paxillin interactions influence focal adhesion signaling that intersects with JNK regulation, while Sfrp4 represses the Ror2/Jnk cascade in osteoclasts to protect cortical bone from excessive endosteal resorption. In zebrafish gastrulation, Jnk signaling negatively regulates Wnt11 expression, illustrating feedback control within developmental networks. From a translational perspective, loss of negative regulation of the JNK cascade contributes to nonalcoholic steatohepatitis under hyperlipidemia, ischemic brain injury, and oncogenic tyrosine phosphatase-driven malignancies. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0046329, its core components, disease relevance, and CRISPR-based methods for functional interrogation.
negative regulation of JNK cascade At A Glance
| GO ID | GO:0046329 |
|---|---|
| GO term | negative regulation of JNK cascade |
| Ontology | biological_process |
| Synonym | down regulation of JNK cascade; down-regulation of JNK cascade; downregulation of JNK cascade; inhibition of JNK cascade |
| Major function | Stops, prevents, or reduces signal transduction mediated by the JNK cascade |
| Biological context | Stress-activated MAPK signaling, inflammation, apoptosis, development |
| Key regulators | Phosphatases, scaffold proteins, secreted antagonists (e.g., Sfrp4), kinase cascades |
| Disease relevance | Cancer, neurodegeneration, NASH, bone resorption disorders |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, imaging |
What Is GO:0046329?
GO:0046329 (negative regulation of JNK cascade) is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the JNK cascade. In practical terms, it encompasses molecular events that dampen JNK pathway output, including inhibition of upstream activators, dephosphorylation of JNK or its substrates, sequestration of pathway components, and feedback loops that terminate JNK signaling.
Why Is negative regulation of JNK cascade Important in Cell Biology?
Negative regulation of the JNK cascade is essential because JNK signaling is a double-edged sword: transient activation supports adaptation and repair, but sustained or unchecked activity drives chronic inflammation, apoptosis, and tissue destruction. The pathway is negatively regulated by diverse mechanisms including calcium/calmodulin-dependent kinase cascades that modulate MAPK activity, sodium-dependent signal transduction that regulates JNK/SAPK, and PI3K/Akt activation that protects neurons by inhibiting JNK signaling. Disruption of these brakes is linked to nonalcoholic steatohepatitis in hyperlipidemia, excessive osteoclast-mediated bone resorption, and oncogenic tyrosine phosphatase-driven cancers. Therefore, GO:0046329 is a high-value target space for both mechanistic studies and therapeutic development.
• Prevents excessive inflammatory signaling by terminating JNK cascade output.
• Protects neurons from ischemic injury through PI3K/Akt-mediated JNK inhibition.
• Controls bone homeostasis by repressing Ror2/Jnk signaling in osteoclasts.
• Limits nonalcoholic steatohepatitis progression under hyperlipidemia.
• Modulates developmental processes such as zebrafish gastrulation via Jnk-Wnt11 feedback.
• Provides a therapeutic handle in cancers driven by oncogenic tyrosine phosphatases.
• Integrates with calcium/calmodulin-dependent kinase cascades to fine-tune MAPK activity.
• Involves scaffold proteins like paxillin that coordinate focal adhesion and stress signaling.
• Offers CRISPR-tractable targets for functional genomics and drug discovery.
• Serves as a paradigm for understanding negative feedback in MAPK networks.
What Happens During negative regulation of JNK cascade?
Upstream inhibition of JNK activators
In simple terms: The pathway is shut off before it fully starts by blocking the molecules that would normally turn JNK on.
Negative regulation of the JNK cascade can begin at the level of upstream activators. For instance, Sfrp4 represses the Ror2/Jnk cascade in osteoclasts, thereby protecting cortical bone from excessive endosteal resorption. In zebrafish gastrulation, Jnk signaling negatively regulates Wnt11 expression, revealing feedback control where Jnk activity itself modulates upstream developmental signals. These examples illustrate that inhibition can occur at receptor or ligand-adjacent nodes rather than only at the terminal kinase.
Phosphatase-mediated dephosphorylation of JNK
In simple terms: Enzymes called phosphatases remove phosphate groups from JNK, switching the kinase off.
Dephosphorylation is a major mechanism for terminating JNK cascade signaling. While specific JNK phosphatases are not detailed in the provided citations, the general principle of phosphatase-mediated negative regulation is well established in MAPK biology. Therapeutic targeting of oncogenic tyrosine phosphatases highlights how phosphatase activity can reshape kinase signaling landscapes. In the context of GO:0046329, phosphatase recruitment to JNK or its upstream kinases represents a direct stop signal for the cascade.
Scaffold and adaptor protein control
In simple terms: Scaffold proteins act like traffic controllers, deciding whether JNK signals proceed or are dampened.
Scaffold and adaptor proteins such as paxillin participate in focal adhesion complexes that intersect with stress-activated MAPK signaling. Paxillin interactions can influence the spatial organization of kinases and phosphatases, thereby modulating the efficiency of JNK cascade transduction. This spatial control is a form of negative regulation because mislocalized or sequestered pathway components cannot efficiently propagate the signal.
Cross-talk with other kinase cascades
In simple terms: Other signaling pathways can put the brakes on JNK by activating opposing kinases.
Negative regulation of the JNK cascade frequently occurs through cross-talk with other kinase pathways. Calcium/calmodulin-dependent protein kinase cascades regulate mitogen-activated protein kinases, providing a mechanism for calcium signals to modulate JNK activity. Similarly, PI3K/Akt activation negatively regulates JNK signaling to protect ischemic brain injury in rat hippocampus. A sodium-dependent signal transduction pathway also regulates a c-Jun amino-terminal kinase/stress-activated protein kinase cascade, demonstrating that ionic and metabolic cues can inhibit JNK. These cross-talk mechanisms ensure that JNK output is contextually appropriate.
Feedback termination and developmental integration
In simple terms: The pathway can shut itself down through feedback loops that are important in development.
Feedback termination is a recurring theme in negative regulation of the JNK cascade. In zebrafish gastrulation, Jnk signaling negatively regulates Wnt11 expression, creating a feedback loop that shapes developmental morphogenesis. In metabolic liver disease, loss of negative control contributes to nonalcoholic steatohepatitis under hyperlipidemia, indicating that feedback brakes are clinically relevant. Together, these examples show that GO:0046329 encompasses both acute termination mechanisms and developmental feedback circuits.
Key Genes Involved in GO:0046329 negative regulation of JNK cascade
The following genes and proteins have been experimentally linked to negative regulation of the JNK cascade or its dysregulation in disease contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PXN (Paxillin) | Scaffold protein in focal adhesions that modulates stress signaling | Studying spatial control of JNK cascade inhibition |
| WNT11 | Negatively regulated by Jnk signaling during zebrafish gastrulation | Developmental feedback models |
| LMO7 | Negatively controls nonalcoholic steatohepatitis in hyperlipidemia | Metabolic liver disease research |
| SFRP4 | Represses Ror2/Jnk cascade in osteoclasts | Bone resorption and osteoclast biology |
| SLC (sodium-dependent transporter) | Regulates JNK/SAPK cascade via sodium-dependent signal transduction | Ion-dependent MAPK regulation |
| PI3K | Activation negatively regulates JNK signaling in ischemic brain injury | Neuroprotection studies |
| AKT | Mediates PI3K-dependent inhibition of JNK | Neuronal survival signaling |
| PTPN (tyrosine phosphatases) | Oncogenic phosphatases that reshape kinase signaling | Cancer therapeutic targeting |
| CAMK (calcium/calmodulin-dependent kinase) | Regulates MAPK including JNK cascade | Calcium signaling cross-talk |
| ROR2 | Receptor tyrosine kinase upstream of Jnk in osteoclasts | Bone biology and Wnt signaling |
| JNK1 (MAPK8) | Core kinase of the JNK cascade | Central node for negative regulation |
| JNK2 (MAPK9) | Core kinase of the JNK cascade | Central node for negative regulation |
| JNK3 (MAPK10) | Neuronal JNK isoform | Neurodegeneration research |
| c-Jun | Downstream substrate of JNK | Transcription factor readout of JNK activity |
| DUSP (dual-specificity phosphatases) | Candidate JNK-inactivating phosphatases | Negative regulation mechanism studies |
How Is negative regulation of JNK cascade Regulated?
Negative regulation of the JNK cascade is itself regulated at multiple levels. Upstream, calcium/calmodulin-dependent protein kinase cascades modulate MAPK activity, providing a calcium-sensitive brake. Sodium-dependent signal transduction pathways can regulate JNK/SAPK cascades, linking ionic homeostasis to pathway inhibition. PI3K/Akt activation negatively regulates JNK signaling, as shown in ischemic brain injury models. Scaffold proteins such as paxillin influence the spatial assembly of signaling complexes that determine whether JNK is activated or inhibited. In disease states, loss of these regulatory inputs contributes to nonalcoholic steatohepatitis and excessive osteoclast activity. Therapeutic targeting of oncogenic tyrosine phosphatases further highlights that phosphatase-dependent regulation is a druggable node within this GO term.
negative regulation of JNK cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LMO7 | Nonalcoholic steatohepatitis (NASH) | Knockout and overexpression in hepatocyte cell lines |
| SFRP4 | Excessive endosteal bone resorption | Osteoclast differentiation models with Sfrp4 KO |
| PI3K/AKT | Ischemic brain injury | Neuronal cell lines with PI3K/Akt overexpression |
| PTPN (tyrosine phosphatases) | Cancer | Cancer cell lines with phosphatase point mutations |
| CAMK | Calcium-dependent MAPK dysregulation | Kinase cascade reconstitution assays |
Cancer and oncogenic phosphatase signaling
Dysregulation of negative regulation of the JNK cascade is implicated in cancer, particularly through oncogenic tyrosine phosphatases that reshape kinase signaling networks. Therapeutic targeting of these phosphatases is an active area of cancer research. Because JNK can promote apoptosis or proliferation depending on context, loss of negative regulation may shift the balance toward tumor-promoting outcomes.
Neurodegeneration and ischemic brain injury
In ischemic brain injury, PI3K/Akt activation negatively regulates JNK signaling to protect rat hippocampal neurons. This neuroprotective mechanism demonstrates that enhancing negative regulation of the JNK cascade can be beneficial in acute neurological injury. JNK3, a neuronal isoform, is a key node where such regulation is relevant.
Metabolic liver disease and NASH
LMO7 negatively controls nonalcoholic steatohepatitis in the setting of hyperlipidemia, linking negative regulation of JNK-related pathways to metabolic liver disease. Loss of this negative control may exacerbate hepatic inflammation and injury under hyperlipidemic conditions. This positions GO:0046329 as a relevant process in NASH pathogenesis.
Bone resorption disorders
Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption. When this negative regulation fails, osteoclast activity may increase, leading to bone loss. This illustrates the importance of GO:0046329 in skeletal homeostasis.
From negative regulation of JNK cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance JNK cascade activity? | CRISPR knockout cell line |
| Does a specific phosphorylation site regulate negative feedback? | Point-mutation knock-in |
| Does a disease-associated variant impair JNK inhibition? | Knock-in of patient variant |
| Where does a negative regulator localize during signaling? | Tagged knock-in (e.g., GFP) |
| Does overexpression of a negative regulator suppress JNK output? | Overexpression cell model |
| Which genes modify negative regulation of JNK cascade? | CRISPR library screening |
How to Study the negative regulation of JNK cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect on JNK cascade | Testing candidate negative regulators |
| Point-mutation knock-in | Site-specific regulatory function | Dissecting phosphorylation sites |
| RNA-seq | Transcriptional output of JNK pathway | Identifying downstream targets |
| Phospho-proteomics | JNK and c-Jun phosphorylation status | Quantifying cascade activity |
| Live-cell imaging | Real-time JNK activity dynamics | Spatial signaling studies |
| Kinase assay | JNK enzymatic activity | In vitro mechanism validation |
| Phosphatase assay | Dephosphorylation of JNK substrates | Negative regulation mechanism |
| CRISPR library screening | Genome-wide modifiers of JNK inhibition | Discovery of novel regulators |
CRISPR knockout and point-mutation models
CRISPR knockout of candidate negative regulators allows direct testing of whether a gene is required to suppress JNK cascade activity. Point-mutation knock-in can dissect specific phosphorylation or interaction sites within regulators such as paxillin or phosphatases. These models are essential for causal inference in GO:0046329 research.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify JNK pathway output and identify downstream transcriptional changes upon loss or gain of negative regulators. For example, Jnk-dependent regulation of Wnt11 expression was revealed through developmental transcriptomics. Proteomic analysis of phospho-JNK and phospho-c-Jun provides direct readouts of cascade activity.
Imaging and spatial signaling assays
Fluorescence imaging of tagged pathway components can reveal how scaffold proteins such as paxillin organize signaling complexes that inhibit JNK. Live-cell imaging of kinase translocation reporters can monitor JNK activity dynamics in real time. These methods complement biochemical assays by providing spatial and temporal resolution.
Biochemical kinase and phosphatase assays
In vitro kinase assays measure JNK activity toward substrates such as c-Jun, while phosphatase assays measure dephosphorylation rates. Calcium/calmodulin-dependent kinase cascade reconstitution can define how cross-talk kinases modulate JNK. Sodium-dependent signal transduction assays can test ion-sensitive regulation of JNK/SAPK.
How CRISPR Can Be Used to Study GO:0046329 negative regulation of JNK cascade
Knockout
CRISPR knockout is used to delete candidate negative regulators of the JNK cascade and measure consequent changes in phospho-JNK, phospho-c-Jun, and downstream transcriptional programs. For example, knocking out Sfrp4 or Lmo7 can test their roles in osteoclast and NASH models, respectively. Knockout models are foundational for establishing necessity within GO:0046329.
Point Mutation
Point-mutation knock-in enables precise interrogation of regulatory residues, such as phosphorylation sites on scaffold proteins or phosphatases that control JNK cascade termination. These models distinguish catalytic from scaffolding functions and reveal feedback mechanisms. They are particularly valuable when complete knockout causes developmental lethality.
Knock-in
Knock-in of disease-associated variants or tagged alleles allows researchers to study how specific mutations affect negative regulation of the JNK cascade in a physiological context. Tagged knock-in (e.g., GFP or luciferase) supports imaging and biochemical tracking of negative regulators. This approach bridges genotype to pathway phenotype.
Overexpression
Overexpression of candidate negative regulators can test sufficiency for JNK cascade inhibition. For instance, activating PI3K/Akt by overexpression suppresses JNK signaling in neuronal models. Overexpression models are also used to study oncogenic tyrosine phosphatases that reshape kinase signaling. Together with knockout, overexpression provides bidirectional causal evidence.
How EDITGENE Supports negative regulation of JNK cascade Research
Researchers studying negative regulation of JNK cascade-related genes often need to determine whether a candidate gene is causally involved in dampening JNK signaling or is merely correlated with pathway output. Establishing causality requires precise genetic models that can delete, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides these CRISPR-enabled models and supporting bioinformatics to accelerate discovery in GO:0046329 research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of JNK cascade research.
Frequently Asked Questions About negative regulation of JNK cascade
What is negative regulation of JNK cascade (GO:0046329)?
It is any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the JNK cascade.
What genes are involved in negative regulation of JNK cascade?
Genes include PXN, WNT11, LMO7, SFRP4, PI3K, AKT, PTPN family phosphatases, and CAMK family kinases, among others.
How is the JNK cascade negatively regulated?
Through upstream inhibition of activators, phosphatase-mediated dephosphorylation, scaffold protein control, cross-talk with other kinase cascades, and feedback termination.
Why is negative regulation of JNK cascade important in disease?
Loss of negative regulation contributes to cancer, neurodegeneration, NASH, and bone resorption disorders.
What diseases are linked to GO:0046329 dysfunction?
Nonalcoholic steatohepatitis, ischemic brain injury, excessive endosteal bone resorption, and oncogenic tyrosine phosphatase-driven cancers.
How can CRISPR be used to study negative regulation of JNK cascade?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models can test necessity and sufficiency of candidate regulators.
What methods measure JNK cascade activity?
Phospho-JNK and phospho-c-Jun immunoblotting, kinase assays, RNA-seq, phospho-proteomics, and live-cell imaging.
Is PI3K/Akt involved in negative regulation of JNK cascade?
Yes, PI3K/Akt activation negatively regulates JNK signaling and protects neurons in ischemic brain injury models.
What is the role of Sfrp4 in JNK regulation?
Sfrp4 represses the Ror2/Jnk cascade in osteoclasts, protecting cortical bone from excessive endosteal resorption.
How does calcium signaling affect negative regulation of JNK cascade?
Calcium/calmodulin-dependent protein kinase cascades regulate mitogen-activated protein kinases including JNK.
Conclusion
GO:0046329 (negative regulation of JNK cascade) is a critical biological process that safeguards cells against excessive stress-activated MAPK signaling. Its mechanisms span upstream inhibition, phosphatase activity, scaffold protein control, kinase cross-talk, and developmental feedback. Dysregulation of this process is implicated in cancer, neurodegeneration, metabolic liver disease, and bone disorders. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with transcriptomic and proteomic readouts, provide powerful tools to dissect these mechanisms and identify therapeutic targets. EDITGENE offers comprehensive services to support such research from model generation to bioinformatics analysis.
References
- 1. Turner CE. 2000. Paxillin interactions.. J Cell Sci 113 Pt 23:4139-40 PMID: 11069756
- 2. Seo J et al.. 2010. Negative regulation of wnt11 expression by Jnk signaling during zebrafish gastrulation.. J Cell Biochem 110(4):1022-37 PMID: 20564202
- 3. Wu T et al.. 2024. LIM domain only 7 negatively controls nonalcoholic steatohepatitis in the setting of hyperlipidemia.. Hepatology 79(1):149-166 PMID: 37676481
- 4. Chen K et al.. 2019. Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption.. Proc Natl Acad Sci U S A 116(28):14138-14143 PMID: 31239337
- 5. Kuroki DW et al.. 1997. Regulation of a c-Jun amino-terminal kinase/stress-activated protein kinase cascade by a sodium-dependent signal transduction pathway.. J Biol Chem 272(38):23905-11 PMID: 9295340
- 6. Hui L et al.. 2005. The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation.. Brain Res 1052(1):1-9 PMID: 16018989
- 7. Frankson R et al.. 2017. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.. Cancer Res 77(21):5701-5705 PMID: 28855209
- 8. Enslen H et al.. 1996. Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade.. Proc Natl Acad Sci U S A 93(20):10803-8 PMID: 8855261
